<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6354">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026389</url>
  </required_header>
  <id_info>
    <org_study_id>DGD 44-045</org_study_id>
    <nct_id>NCT01026389</nct_id>
  </id_info>
  <brief_title>Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease</brief_title>
  <acronym>DALIA</acronym>
  <official_title>Efficacy Evaluation of Dotarem®-Enhanced MRA Compared to Gadovist®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Limb Arterial Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Spain: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an efficacy evaluation of Dotarem®-enhanced magnetic resonance angiography
      (MRA) compared to Gadovist®-enhanced MRA in the diagnosis of clinically significant
      abdominal or lower limb arterial diseases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Intra-patient Accuracy (Percent Agreement), On-site Data</measure>
    <time_frame>up to one month</time_frame>
    <safety_issue>No</safety_issue>
    <description>intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-patient Accuracy, in Off-site Readings</measure>
    <time_frame>up to one month</time_frame>
    <safety_issue>No</safety_issue>
    <description>• Intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography, in off-site readings, using the same methodology as that used for the primary criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>up to one month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Specificity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site readings; no stenosis and non significant stenosis were grouped as one class (non significant stenosis = negative segment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>up to one month</time_frame>
    <safety_issue>No</safety_issue>
    <description>sensitivity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site; moderate, severe stenosis and occlusion were grouped as one class (significant stenosis = positive segment).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Gadovist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient received contrast-enhanced MRA with Gadovist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dotarem, interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received contrast-enhanced MRA with Dotarem</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dotarem</intervention_name>
    <description>DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus</description>
    <arm_group_label>Dotarem, interventional</arm_group_label>
    <other_name>gadoterate</other_name>
    <other_name>Gd-Dota</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadovist</intervention_name>
    <description>Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus</description>
    <arm_group_label>Gadovist</arm_group_label>
    <other_name>gadobutrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged ≥ 18 years.

          -  Patient with infrarenal aorta or chronic lower limb ischemia with various clinical
             signs of gravity (stages II-IV according to the classification of Leriche and
             Fontaine) or/and Doppler ultrasonography indicating abdominal or lower limb
             arteriopathy.

          -  Patient scheduled for a conventional X-Ray angiography (intra-arterial Digital
             Substraction Angiography = DSA) within 30 days of MRA with a minimum time interval of
             at least 24 hours between the 2 examinations.

        Exclusion Criteria:

          -  Patient planned to undergo therapeutic intervention in abdominal or lower limb
             vessels between the time of MRA and X-ray Angiography will be performed.

          -  Patient who had a major cardiovascular event within 30 days prior to the inclusion.

          -  Patient treated with unilateral hip replacement, abdominal aortic or iliac graft or
             stent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AKH hospital</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 14, 2012</lastchanged_date>
  <firstreceived_date>December 3, 2009</firstreceived_date>
  <firstreceived_results_date>November 14, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRA-Contrast agent comparison in peripheral disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gadobutrol</mesh_term>
    <mesh_term>Gadoterate meglumine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period between october 2009 and January 2011. Patients were recruited in hospitals.</recruitment_details>
      <pre_assignment_details>3 patients were not randomized: 2 patients because of technical issue and one patient because of sponsor decision (inclusion period finished/ number of evaluable patients achieved)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gadovist</title>
          <description>Patient received contrast-enhanced MRA with Gadovist</description>
        </group>
        <group group_id="P2">
          <title>Dotarem</title>
          <description>Patients received contrast-enhanced MRA with Dotarem</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>change of treatment, patient moved</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gadovist</title>
          <description>Patient received contrast-enhanced MRA with Gadovist</description>
        </group>
        <group group_id="B2">
          <title>Dotarem, Interventional</title>
          <description>Patients received contrast-enhanced MRA with Dotarem</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="93"/>
                <measurement group_id="B2" value="93"/>
                <measurement group_id="B3" value="186"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="48"/>
                <measurement group_id="B3" value="96"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
                <measurement group_id="B2" value="45"/>
                <measurement group_id="B3" value="90"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="66.5" spread="10.2"/>
                <measurement group_id="B2" value="66.8" spread="10.6"/>
                <measurement group_id="B3" value="66.7" spread="10.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="72"/>
                <measurement group_id="B2" value="75"/>
                <measurement group_id="B3" value="147"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Austria</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="37"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>France</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="36"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Italy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Spain</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="67"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intra-patient Accuracy (Percent Agreement), On-site Data</title>
        <description>intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography.</description>
        <time_frame>up to one month</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Gadovist</title>
            <description>Patient received contrast-enhanced MRA with Gadovist</description>
          </group>
          <group group_id="O2">
            <title>Dotarem, Interventional</title>
            <description>Patients received contrast-enhanced MRA with Dotarem</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="87"/>
                  <measurement group_id="O2" value="86"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Intra-patient Accuracy (Percent Agreement), On-site Data</title>
            <description>intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography.</description>
            <units>percentage of agreement</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="77.1" spread="19.6"/>
                  <measurement group_id="O2" value="80.6" spread="16.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intra-patient Accuracy, in Off-site Readings</title>
        <description>• Intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography, in off-site readings, using the same methodology as that used for the primary criterion</description>
        <time_frame>up to one month</time_frame>
        <safety_issue>No</safety_issue>
        <population>Ecah images from each patient were analysed by two external readers, this means that each patient was analyzed twice.
Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Gadovist</title>
            <description>Patient received contrast-enhanced MRA with Gadovist</description>
          </group>
          <group group_id="O2">
            <title>Dotarem, Interventional</title>
            <description>Patients received contrast-enhanced MRA with Dotarem</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="78"/>
                  <measurement group_id="O2" value="76"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of images analyzed</title>
            <units>images</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="152"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Intra-patient Accuracy, in Off-site Readings</title>
            <description>• Intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography, in off-site readings, using the same methodology as that used for the primary criterion</description>
            <units>percentage of agreement</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75.1" spread="15.3"/>
                  <measurement group_id="O2" value="73.9" spread="16.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specificity</title>
        <description>Specificity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site readings; no stenosis and non significant stenosis were grouped as one class (non significant stenosis = negative segment).</description>
        <time_frame>up to one month</time_frame>
        <safety_issue>No</safety_issue>
        <population>per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Gadovist</title>
            <description>Patient received contrast-enhanced MRA with Gadovist</description>
          </group>
          <group group_id="O2">
            <title>Dotarem, Interventional</title>
            <description>Patients received contrast-enhanced MRA with Dotarem</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                  <measurement group_id="O2" value="77"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Negative segment with gold standard analyzed</title>
            <units>Negative segment with gold standard</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="819"/>
                  <measurement group_id="O2" value="824"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Specificity</title>
            <description>Specificity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site readings; no stenosis and non significant stenosis were grouped as one class (non significant stenosis = negative segment).</description>
            <units>negative segments in MRA</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="756"/>
                  <measurement group_id="O2" value="763"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity</title>
        <description>sensitivity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site; moderate, severe stenosis and occlusion were grouped as one class (significant stenosis = positive segment).</description>
        <time_frame>up to one month</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Gadovist</title>
            <description>Patient received contrast-enhanced MRA with Gadovist</description>
          </group>
          <group group_id="O2">
            <title>Dotarem, Interventional</title>
            <description>Patients received contrast-enhanced MRA with Dotarem</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                  <measurement group_id="O2" value="77"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of positive segment with gold standard analyzed</title>
            <units>positive segment with gold standard</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="238"/>
                  <measurement group_id="O2" value="264"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sensitivity</title>
            <description>sensitivity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site; moderate, severe stenosis and occlusion were grouped as one class (significant stenosis = positive segment).</description>
            <units>positive segment with MRA</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="168"/>
                  <measurement group_id="O2" value="191"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 months in total For each patient, adverse events were collected from signature of inform consent form to the end of the DSA</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gadovist</title>
          <description>Patient received contrast-enhanced MRA with Gadovist</description>
        </group>
        <group group_id="E2">
          <title>Dotarem, Interventional</title>
          <description>Patients received contrast-enhanced MRA with Dotarem</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <description>Not related, occured prior to administration of study treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>carotid stenosis</sub_title>
                <description>Not related, occured prior to administration of study treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.01</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>contrast extravasation</sub_title>
                <description>Not related, mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculis</sub_title>
                <description>Not related, mild</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>burning</sub_title>
                <description>Possibly related, mild</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>heat sensation in the face</sub_title>
                <description>Possibly related, mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Post M. A. Clinical Unit Manager</name_or_title>
      <organization>Guerbet</organization>
      <phone>+33 1 45 91 50 00</phone>
      <email>corinne.dubourdieu@guerbet-group.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
